#5-37E. Targeting the Nucleus of Lupus: TLR7/8 Antagonism and the Era of Precision Rheumatology (Nat Rev Rheumatol, 2026)

How can we transition from broad immunosuppression to highly targeted, personalized therapies for systemic lupus erythematosus (SLE)? This pivotal review discusses how the TLR7 signaling pathway, driven by genetic gain-of-function variants in TLR7 and UNC93B1, acts as a primary initiator of SLE by hyperactivating endosomal nucleic acid sensing, leading to autoantibody production and elevated type I interferon. Excitingly, the authors highlight that novel oral TLR7/8 antagonists, such as enpatoran, have demonstrated robust suppression of the type I interferon signature and encouraging clinical efficacy in early-phase trials. However, as critical readers, we must note that these findings are currently constrained by small sample sizes and the short duration of early-phase studies, necessitating larger trials to confirm long-term safety and efficacy. For clinicians, understanding this pathway is crucial as it heralds a paradigm shift toward precision medicine, offering potential oral, non-steroidal options that target the disease's underlying genetic drivers.Citation: Carola G. Vinuesa, Madhumita Shrotri, Anisur Rahman. TLR7 in systemic lupus erythematosus: genetics and emerging therapies. Nature Reviews Rheumatology. 2026. DOI: 10.1038/s41584-026-01388-0

URL: https://doi.org/10.1038/s41584-026-01388-0

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.